208 related articles for article (PubMed ID: 29678300)
1. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
Yan Q; Karau MJ; Patel R
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
Neudorfer K; Schmidt-Malan SM; Patel R
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
[TBL] [Abstract][Full Text] [Related]
4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
6. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
[TBL] [Abstract][Full Text] [Related]
8. New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE.
Szűcs Z; Ostorházi E; Kicsák M; Nagy L; Borbás A; Herczegh P
J Antibiot (Tokyo); 2019 Jul; 72(7):524-534. PubMed ID: 30874609
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oritavancin and nisin alone and their combination against vancomycin resistant enterococci strains in hospitalized patients in Turkiye.
Sefali S; Y N
Indian J Med Microbiol; 2024; 47():100489. PubMed ID: 37890415
[TBL] [Abstract][Full Text] [Related]
10. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
[TBL] [Abstract][Full Text] [Related]
11. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Carvalhaes CG; Sader HS; Streit JM; Castanheira M; Mendes RE
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0166721. PubMed ID: 34807761
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
Dahesh S; Wong B; Nizet V; Sakoulas G; Tran TT; Aitken SL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235559
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
J Glob Antimicrob Resist; 2017 Mar; 8():28-32. PubMed ID: 27939809
[TBL] [Abstract][Full Text] [Related]
14. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.
Arhin FF; Moeck G
J Glob Antimicrob Resist; 2017 Jun; 9():85-86. PubMed ID: 28455075
[No Abstract] [Full Text] [Related]
15. Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin.
Shlezinger M; Coppenhagen-Glazer S; Gelman D; Beyth N; Hazan R
Viruses; 2019 Oct; 11(10):. PubMed ID: 31623253
[TBL] [Abstract][Full Text] [Related]
16. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant
Tong J; Jiang Y; Xu H; Jin X; Zhang L; Ying S; Yu W; Qiu Y
Drug Des Devel Ther; 2021; 15():3049-3055. PubMed ID: 34285472
[TBL] [Abstract][Full Text] [Related]
17.
Brown Gandt A; Griffith EC; Lister IM; Billings LL; Han A; Tangallapally R; Zhao Y; Singh AP; Lee RE; LaFleur MD
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784838
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
19. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
Arhin FF; Seguin DL; Belley A; Moeck G
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
[TBL] [Abstract][Full Text] [Related]
20. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
[No Abstract] [Full Text] [Related]
[Next] [New Search]
